Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fostamatinib

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Optime Care Expands Partnership With Rigel For Tavalisse Distribution
    Optime Care Expands Partnership With Rigel For Tavalisse Distribution

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2964215/0/en/Optime-Care-Expands-Partnership-with-Rigel-Pharmaceuticals-to-Include-Commercial-Distribution-for-TAVALISSE.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    Annora Pharma`s Generics Fostamatinib Receives Approval in US
    Annora Pharma`s Generics Fostamatinib Receives Approval in US

    23 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217329

    FDA
    23 Sep 2024
    Share Share
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
    Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

    10 Oct 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-provides-update-on-plans-for-snda-for-waiha-program-following-fda-feedback-301645117.html#:~:text=Rigel%20also%20announced%20today%20that,the%20fourth%20quarter%20of%202022.

    PRNEWSWIRE
    10 Oct 2022
    Share Share
    Rigel Announces Top-line Results from FORWARD PIII Trial of Fostamatinib
    Rigel Announces Top-line Results from FORWARD PIII Trial of Fostamatinib

    08 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-top-line-results-from-forward-phase-3-clinical-trial-of-fostamatinib-in-patients-with-warm-autoimmune-hemolytic-anemia-301563691.html

    PRNEWSWIRE
    08 Jun 2022
    Share Share
    Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan
    Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan

    21 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/fostamatinib-meets-primary-endpoint-in-phase-3-trial-in-japan-for-treatment-of-chronic-immune-thrombocytopenia-301448726.html

    PRNEWSWIRE
    21 Dec 2021
    Share Share